Thomas Powles, MBBS, MRCP, MD, joins the Oncology Brothers, Rohit Gosain, MD, and Rahul Gosain, MD, to discuss the EV-302 study and the role of enfortumab vedotin plus pembrolizumab in the bladder cancer treatment landscape.
EP. 1: EV-302 Study Design and Results
Thomas Powles, MBBS, MRCP, MD, joins the Oncology Brothers to discuss the study design and results of the EV-302 trial investigating enfortumab vedotin plus pembrolizumab in untreated advanced urothelial carcinoma.
Watch
EP. 2: The Role of Enfortumab Vedotin Plus Pembrolizumab in Bladder Cancer
The Oncology Brothers are joined by Thomas Powles, MBBS, MRCP, MD, to discuss the role of enfortumab vedotin plus pembrolizumab in the bladder cancer treatment landscape.
EP. 3: Safety Profile Considerations for Enfortumab Vedotin Plus Pembrolizumab
A comprehensive discussion on treatment-related adverse events seen in patients receiving enfortumab vedotin and pembrolizumab.
EP. 4: The Role of Circulating Tumor DNA in Bladder Cancer
Following a discussion centered on the EV-302 study, Thomas Powles, MBBS, MRCP, MD, and the Oncology Brothers discuss the role of circulating tumor DNA in urothelial cancer.